Ziwig

Executive Summary

Ziwig is a French biotechnology company leveraging artificial intelligence and salivary RNA analysis to develop non-invasive diagnostic tests, with an initial focus on endometriosis. Founded in 2019 and headquartered in Paris, the company combines fundamental molecular biology research with industrial-scale laboratory operations to create accessible diagnostic solutions. Its flagship product, Endotest, analyzes salivary RNA patterns to detect endometriosis, a condition affecting ~10% of women that currently requires invasive laparoscopy for diagnosis. By replacing invasive procedures with a simple saliva test, Ziwig aims to reduce diagnostic delays, which average 7–10 years, and improve patient outcomes. The company's AI-driven platform has the potential to be extended to other women's health indications beyond endometriosis, positioning it as a leader in precision diagnostics. Ziwig addresses a large unmet need in women's health, where non-invasive diagnostic options are scarce. The global endometriosis diagnostics market is projected to grow significantly as awareness increases. With its proprietary technology and scalable lab operations, Ziwig is well positioned to capture early market share in Europe and potentially expand to the US and Asia pending regulatory clearances. Key risks include regulatory hurdles, competition from emerging diagnostic methods, and the need for commercial partnerships to drive adoption. However, the company's innovative approach and strong scientific foundation suggest a promising trajectory in the high-growth diagnostics sector.

Upcoming Catalysts (preview)

• Q3 2026CE Marking for Endotest in Europe70% success
• Q2 2026Publication of pivotal clinical validation study results75% success
• Q4 2026Formation of strategic partnership with a large diagnostics or pharmaceutical company50% success